8 results about "Exotoxin" patented technology

The present disclosure provides a method for treating sepsis caused by a microorganism infection. The disclosure also relates to a method for identifying and discovering compounds useful in treating sepsis as well as a method for determining appropriate approaches for treating sepsis. In particular, the methods of the disclosure are based on the discovery by the present inventor that sepsis is caused by exotoxin(s) of microorganism or by constitutive proteins that function as exotoxins as in the case of viruses.

The application discloses a nano antibody against PE toxin, wherein the nano antibody has three unique complementarity determining regions CDR1, CDR2 and CDR3, and the application also discloses application of the nano antibody in preparation of anti-PE toxin drugs. The anti-PE toxin nano antibody provided by the application has specific recognition and combination capacity for PE toxin, and has the effect of efficiently neutralizing PE toxin toxicity, thereby protecting cells.

The application discloses a p-hydroxycinnamaldehyde modified sphingomyelin liposome and application thereof in anti-MRSA infection. The p-hydroxycinnamaldehyde is bonded with the sphingomyelin through a two-step esterification reaction to obtain a bonding product sphingomyelin-p-hydroxycinnamaldehyde, and the p-hydroxycinnamaldehyde modified sphingomyelin liposome is prepared through a film hydration method. The liposome provided by the application is spherical, and the particle size distribution is uniform. The sphingomyelin component in the liposome can effectively neutralize the exotoxin of MRSA, and relieve the damage of the exotoxin of MRSA to normal cells of the body. The p-hydroxycinnamaldehyde in the liposome can induce the M0 type and M2 type macrophages in the body to polarize into M1 type macrophages with stronger phagocytosis and killing ability, relieve the immunosuppression caused by MRSA infection, and enhance the clearance ability of the macrophages to MRSA. The liposome provided by the application has application prospects in the preparation of drugs or preparations for treating diseases caused by MRSA infection.

The present disclosure provides a method for treating sepsis caused by a microorganism infection. The disclosure also relates to a method for identifying and discovering compounds useful in treating sepsis as well as a method for determining appropriate approaches for treating sepsis. In particular, the methods of the disclosure are based on the discovery by the present inventor that sepsis is caused by exotoxin(s) of microorganism or by constitutive proteins that function as exotoxins as in the case of viruses.

The application provides a pertussis antigen recombinant expression vector and engineering bacteria and application thereof. The pertussis antigen recombinant expression vector comprises a resistance screening gene, an upstream recombinant nucleic acid fragment of a pertussis exotoxin gene and a downstream recombinant nucleic acid fragment, wherein the upstream and downstream recombinant nucleic acid fragments can respectively perform homologous recombination with the upstream and downstream of the pertussis exotoxin gene. The application takes the pertussis bacillus as a host, constructs an engineering bacteria ΔPT strain for producing FHA and PRN by knocking out the PT gene, simplifies the production process of the FHA and PRN antigens, maintains the high purity and immunogenicity of the FHA and PRN antigens, eliminates the interference of the PT protein in the production of the FHA and PRN antigens, avoids the PT protein detoxification process, and eliminates the risk of possible PT protein toxicity reversal.

Provided is use of a recombinant nucleic acid construct containing a B7-2-PE40 exotoxin fusion gene in the preparation of a DNA vaccine or medicament for treatment and / or prevention of type 1 diabetes. The DNA vaccine can reduce blood glucose in patient with type 1 diabetes, restore the secretion of insulin of the patients per se, and reduce the contents of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) in the patients.

The invention discloses a pathogen infection diagnosis marker based on DPH gene family mRNA and diphtheria amide modification level, a kit and application. The marker combination comprises the mRNA expression level of the DPH1-DPH7 gene and the diphtheria amide modification level of the eukaryotic elongation factor 2. The invention reveals that the combination is remarkably related to pathogen infection for the first time, and provides a detection kit containing a specific primer, biotinylated NAD, pseudomonas exotoxin A and other reagents. The indexes are respectively detected through qPCR (quantitative polymerase chain reaction) and non-denatured immunoblotting, and efficient diagnosis can be realized through combined analysis. Experiments show that the combined marker is excellent in diagnostic performance, the area AUC under a curve of a combined logistic regression model can reach 0.917, the sensitivity is 90.9%, the specificity is 85.7%, and a novel and reliable molecular scheme is provided for early-stage differential diagnosis of infection.

The present application relates to the field of biotechnology, and application of a kuding tea and its extract and a product for preventing or treating hypertension. The product has the following effects: reducing the abundance of staphylococcus aureus (SA) in the intestinal tract or / and regulating the composition of the intestinal flora; reducing the level of at least one exotoxin secreted by SA in the body; up-regulating the expression of at least one of glutathione S-transferase and glutathione S-transferase P1 in the hypothalamic paraventricular nucleus. The present application also provides application of GSTM2 / GSTP1 as a target point in a product for preventing or treating hypertension. The present application is applied to a product for up-regulating the antioxidant defense (GSTM2 / GSTP1) of the hypothalamic paraventricular nucleus (PVN) through intestinal SA-exotoxin, and is further applied to prevention and treatment of hypertension. The present application provides a new target point for intervention in reducing blood pressure, and thus prepares a new product such as a drug for preventing and treating hypertension.